Streetbeat News

Corporate News

CROX

Levi & Korsinsky law firm is preparing a class action securities lawsuit against Crocs, Inc. alleging securities fraud between November 2022 and October 2024. The lawsuit claims Crocs made false statements about HEYDUDE brand revenue growth, specifically that 2022 revenue was artificially inflated by stocking third-party wholesalers and retailers following the February 2022 acquisition.

Portfolio Pulse from

March 23, 2025 | 11:45 am

ESTC

A class action lawsuit has been filed against Elastic N.V. alleging securities fraud between May 31, 2024 and August 29, 2024. The complaint claims the company made false statements about its sales operations, customer segments, and revenue guidance for fiscal year 2025, potentially misleading investors.

Portfolio Pulse from

March 23, 2025 | 11:45 am

NVDA

TSLA

The article compares analyst sentiments on Tesla and Nvidia, highlighting divergent views. While Tesla is a battleground stock with mixed analyst recommendations, Nvidia receives near-unanimous buy ratings. Both stocks have experienced significant price declines this year, with Tesla down 38% and Nvidia down 13%.

Portfolio Pulse from

March 23, 2025 | 11:45 am

TTD

A class action securities lawsuit has been filed against The Trade Desk (TTD) alleging securities fraud between May 9, 2024, and February 12, 2025. The lawsuit claims the company made false statements about its AI forecasting tool Kokai's rollout, execution challenges, and potential negative impacts on revenue growth.

Portfolio Pulse from

March 23, 2025 | 11:45 am

NTLA

Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.

Portfolio Pulse from

March 23, 2025 | 11:45 am

ARNC

Law firm Levi & Korsinsky is initiating a class action lawsuit against Arconic Corporation for allegedly making false statements about its share repurchase programs. The lawsuit claims Arconic made stock buybacks while possessing material nonpublic information and during ongoing negotiations with Apollo, which violated securities trading rules.

Portfolio Pulse from

March 23, 2025 | 11:45 am

TMDX

A class action lawsuit has been filed against TransMedics Group, Inc. (TMDX) alleging securities fraud between February 28, 2023 and January 10, 2025. The lawsuit claims the company used fraudulent business practices, including kickbacks, overbilling, and unsafe practices, which potentially misled shareholders about the company's true operational status.

Portfolio Pulse from

March 23, 2025 | 11:45 am

MODV

Law firm Levi & Korsinsky has filed a class action securities lawsuit against ModivCare Inc. (MODV) alleging securities fraud between November 2022 and September 2024. The lawsuit claims the company made false statements about its financial condition, specifically regarding contract issues in its Non-Emergency Medical Transportation (NEMT) segment that negatively impacted free cash flow, adjusted EBITDA, and liquidity.

Portfolio Pulse from

March 23, 2025 | 11:45 am

VG

Venture Global (VG) is facing a class action lawsuit related to its January 2025 IPO. The lawsuit alleges that the company's registration statement was false or misleading after TotalEnergies rejected a long-term customer contract, citing lack of trust. Additionally, existing clients BP and Shell are challenging Venture Global due to supply contract delays, potentially undermining the company's ability to develop its natural gas liquefaction and export projects.

Portfolio Pulse from

March 23, 2025 | 11:45 am

GSK

Law firm Levi & Korsinsky has filed a class action securities lawsuit against GSK plc, alleging securities fraud between February 2020 and August 2022. The lawsuit claims GSK misled investors about the Zantac withdrawal and potential cancer risks, suggesting the company knew about NDMA sources for decades before removing the drug from the market.

Portfolio Pulse from

March 23, 2025 | 11:45 am